Lignosus Rhinoceros TM02® as a Complementary Therapy for Uncontrolled Asthma

Summary

The goal of this clinical trial is to learn if TM02® works to treat partially controlled or uncontrolled asthma in adults. It will also learn about the efficacy and safety of TM02®. The main questions it aims to answer are: Does TM02® causes bronchodilation (to what extent), improves asthma control, and reduces airway inflammation and blood eosinophils and serum immunoglobulin E levels. Participants will: Take TM02® every day for 90 days. Visit the clinic once every 30 days for checkups, tests and to fill up questionnaires. Keep a diary of their symptoms and the number of times they use a rescue inhaler.

Timeline

Start

2022-03-01

Primary completion

2023-02-28

Completion

2023-02-28

Drugs

Indications